Deferasirox Decreases Busulfan Clearance

Abstract

Get full access to this article

View all access options for this article.

References

Ten Brink

Zwaveling

Swen

Bredius

Lankester

Guchelaar

HJ.

Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics. Drug Discov Today. 2014;19:1572-1586. doi:10.1016/j.drudis.2014.04.005

Bartelink

Bredius

Belitser

et al . Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:231-241. doi:10.1016/j.bbmt.2008.11.022

Busulfex (busulfan) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical; 2015.

Sweiss

Patel

Rondelli

Deferasirox increases BU blood concentrations. Bone Marrow Transplant. 2012;47:315-316. doi:10.1038/bmt.2011.75

Horn

Hansten

Chan

LN.

Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-680. doi:10.1345/aph.1H423